NCT02092792View on ClinicalTrials.gov

A Study Evaluating the Safety of Escalating Doses of DLYE5953A in Patients With Refractory Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

April 1, 2014

Primary Completion Date

July 10, 2017

Study Completion Date

July 10, 2017

Conditions
Neoplasms
Interventions
DRUG

DLYE5953A

Escalating doses of DLYE5953A

DRUG

DLYE5953A

Administration of DLYE5953A at the recommended phase II dose (RP2D)

Trial Locations (5)

10065

Memorial Sloan-Kettering Cancer Center, New York

48201

Karmanos Cancer Center, Detroit

80045

University of Colorado Cancer Center, Aurora

06520

Yale Cancer Center; Medical Oncology, New Haven

02115

Dana Farber Cancer Inst., Boston

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY